Fruquintinib Capsules

Fruquintinib capsules are related drugs for the treatment of rectal cancer. The main clinical indications are:
It is suitable for patients with metastatic colorectal cancer who have previously received chemotherapy based on fluorouracil, oxaliplatin and irinotecan.
It is suitable for patients with metastatic colorectal cancer who have previously received or are not suitable for anti-vascular endothelial growth factor therapy and anti-epidermal growth factor receptor therapy.
The main target of Fruquintinib capsules is VEGFR kinase family VEGFR1, 2 and 3; by inhibiting VEGFR phosphorylation and downstream signal transduction on the surface of mesenchymal endothelial cells, inhibiting the proliferation, migration and lumen formation of mesenchymal endothelial cells, thereby inhibiting the formation of tumor angiogenesis, and ultimately exerting a tumor growth inhibitory effect.